SG11201406914XA - Alpha 7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof - Google Patents
Alpha 7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereofInfo
- Publication number
- SG11201406914XA SG11201406914XA SG11201406914XA SG11201406914XA SG11201406914XA SG 11201406914X A SG11201406914X A SG 11201406914XA SG 11201406914X A SG11201406914X A SG 11201406914XA SG 11201406914X A SG11201406914X A SG 11201406914XA SG 11201406914X A SG11201406914X A SG 11201406914XA
- Authority
- SG
- Singapore
- Prior art keywords
- alpha
- derivatives
- acetylcholine receptor
- nicotinic acetylcholine
- allosteric modulators
- Prior art date
Links
- 230000003281 allosteric effect Effects 0.000 title 1
- 102000047725 alpha7 Nicotinic Acetylcholine Receptor Human genes 0.000 title 1
- 108700006085 alpha7 Nicotinic Acetylcholine Receptor Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261644411P | 2012-05-08 | 2012-05-08 | |
| US201261644318P | 2012-05-08 | 2012-05-08 | |
| US201261645935P | 2012-05-11 | 2012-05-11 | |
| US201361801544P | 2013-03-15 | 2013-03-15 | |
| PCT/US2013/040117 WO2013169889A1 (en) | 2012-05-08 | 2013-05-08 | Alpha 7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201406914XA true SG11201406914XA (en) | 2014-11-27 |
Family
ID=48430966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201406914XA SG11201406914XA (en) | 2012-05-08 | 2013-05-08 | Alpha 7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20150099758A1 (enEXAMPLES) |
| EP (1) | EP2846803B1 (enEXAMPLES) |
| JP (1) | JP2015516429A (enEXAMPLES) |
| KR (1) | KR20150008891A (enEXAMPLES) |
| CN (1) | CN104334175A (enEXAMPLES) |
| AU (1) | AU2013259565A1 (enEXAMPLES) |
| BR (1) | BR112014027561A2 (enEXAMPLES) |
| CA (1) | CA2871651A1 (enEXAMPLES) |
| EA (1) | EA201491857A1 (enEXAMPLES) |
| HK (1) | HK1208154A1 (enEXAMPLES) |
| IN (1) | IN2014MN02121A (enEXAMPLES) |
| MX (1) | MX2014013499A (enEXAMPLES) |
| SG (1) | SG11201406914XA (enEXAMPLES) |
| WO (1) | WO2013169889A1 (enEXAMPLES) |
| ZA (1) | ZA201408847B (enEXAMPLES) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170217946A1 (en) * | 2014-07-25 | 2017-08-03 | Bayer Pharma Aktiengesellschaft | Amino-substituted isoxazoles |
| EP2977377A1 (en) * | 2014-07-25 | 2016-01-27 | Bayer Pharma Aktiengesellschaft | Amino-substituted isoxazoles |
| EP2977376A1 (en) * | 2014-07-25 | 2016-01-27 | Bayer Pharma Aktiengesellschaft | Amino-substituted isoxazoles |
| EP2977375A1 (en) * | 2014-07-25 | 2016-01-27 | Bayer Pharma Aktiengesellschaft | Amino-substituted isoxazoles |
| CN107398300B (zh) * | 2017-07-24 | 2020-08-21 | 中国科学院化学研究所 | 芳香族酰胺芳环c-h键直接氨基化反应的方法 |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
| US11472791B2 (en) | 2019-03-05 | 2022-10-18 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors |
| US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
| US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| AR119765A1 (es) | 2019-08-14 | 2022-01-12 | Incyte Corp | Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2 |
| EP4041731A1 (en) | 2019-10-11 | 2022-08-17 | Incyte Corporation | Bicyclic amines as cdk2 inhibitors |
| WO2022096990A1 (en) * | 2020-11-05 | 2022-05-12 | Cadila Healthcare Limited | Novel hetrocyclic compounds |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0001930D0 (en) * | 2000-01-27 | 2000-03-22 | Novartis Ag | Organic compounds |
| CN1440393A (zh) * | 2000-04-28 | 2003-09-03 | 田边制药株式会社 | 环状化合物 |
| US20020147198A1 (en) * | 2001-01-12 | 2002-10-10 | Guoqing Chen | Substituted arylamine derivatives and methods of use |
| JP2008525524A (ja) * | 2004-12-28 | 2008-07-17 | アストラゼネカ・アクチエボラーグ | アリールスルホンアミドモジュレーター |
| US20060173019A1 (en) * | 2005-01-14 | 2006-08-03 | Solomon Ungashe | Heteroaryl sulfonamides and CCR2 |
| US7622583B2 (en) * | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
| US8519135B2 (en) * | 2006-07-14 | 2013-08-27 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2/CCR9 |
| AR071203A1 (es) * | 2008-04-17 | 2010-06-02 | Glaxo Group Ltd | Compuesto de trifluorometil-indol-carboxamida, su uso para la fabricacion de un medicamento util para el tratamiento de un trastorno psicotico o deterioro cognitivo y composicion farmaceutica que lo comprende |
| BR112012007747B8 (pt) * | 2009-10-06 | 2021-05-25 | Millennium Pharm Inc | compostos heterocíclicos úteis como inibidores de pdk1, sua composição farmacêutica e seus usos |
| GB201106829D0 (en) * | 2011-04-21 | 2011-06-01 | Proximagen Ltd | Heterocyclic compounds |
-
2013
- 2013-05-08 IN IN2121MUN2014 patent/IN2014MN02121A/en unknown
- 2013-05-08 CA CA2871651A patent/CA2871651A1/en not_active Abandoned
- 2013-05-08 SG SG11201406914XA patent/SG11201406914XA/en unknown
- 2013-05-08 EP EP13722661.9A patent/EP2846803B1/en not_active Not-in-force
- 2013-05-08 EA EA201491857A patent/EA201491857A1/ru unknown
- 2013-05-08 KR KR20147033675A patent/KR20150008891A/ko not_active Withdrawn
- 2013-05-08 JP JP2015511659A patent/JP2015516429A/ja active Pending
- 2013-05-08 CN CN201380029104.9A patent/CN104334175A/zh active Pending
- 2013-05-08 US US14/398,968 patent/US20150099758A1/en not_active Abandoned
- 2013-05-08 BR BR112014027561A patent/BR112014027561A2/pt not_active IP Right Cessation
- 2013-05-08 MX MX2014013499A patent/MX2014013499A/es unknown
- 2013-05-08 AU AU2013259565A patent/AU2013259565A1/en not_active Abandoned
- 2013-05-08 HK HK15108755.1A patent/HK1208154A1/xx unknown
- 2013-05-08 WO PCT/US2013/040117 patent/WO2013169889A1/en active Application Filing
-
2014
- 2014-12-03 ZA ZA2014/08847A patent/ZA201408847B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013259565A1 (en) | 2014-11-13 |
| ZA201408847B (en) | 2015-12-23 |
| HK1208154A1 (en) | 2016-02-26 |
| US20150099758A1 (en) | 2015-04-09 |
| CN104334175A (zh) | 2015-02-04 |
| EA201491857A1 (ru) | 2015-04-30 |
| IN2014MN02121A (enEXAMPLES) | 2015-09-04 |
| BR112014027561A2 (pt) | 2017-06-27 |
| KR20150008891A (ko) | 2015-01-23 |
| EP2846803A1 (en) | 2015-03-18 |
| EP2846803B1 (en) | 2017-06-21 |
| JP2015516429A (ja) | 2015-06-11 |
| CA2871651A1 (en) | 2013-11-14 |
| MX2014013499A (es) | 2015-11-13 |
| WO2013169889A1 (en) | 2013-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201408847B (en) | Alpha 7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof | |
| IL274988A (en) | Carbamoylpyridone-polycyclic compounds and their pharmaceutical use | |
| IL236036A0 (en) | Pyridinone and pyridizinone derivatives | |
| IL233592A0 (en) | p2x4 receptor antagonist | |
| EP2828258A4 (en) | NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND THEIR USE | |
| IL237068A (en) | 1,3-dioxanomorphides and 1,3-dioxanocodides | |
| IL236057B (en) | History of 4,2,1-triazine-6-carboxamide and pharmaceutical preparations containing them | |
| EP2901346A4 (en) | SAFETY TESTING OF AN APPLICATION | |
| IL238060B (en) | 2-aminopyridine derivatives, their preparation and pharmaceutical compositions containing them | |
| ZA201503367B (en) | Heteroaryl derivatives and uses thereof | |
| EP2877926A4 (en) | SAFETY TESTING OF AN APPLICATION | |
| PL2650310T3 (pl) | Przeciwciało przeciw-ADAMTS-5, jego pochodne i zastosowania | |
| IL239146A0 (en) | Aminocyclobutane derivatives, methods for their preparation and their use as drugs | |
| IL238629A0 (en) | Antibodies against prokinectin receptor and their uses | |
| IL220839A0 (en) | Nicotinic acetylcholine receptor modulators | |
| EP2930175A4 (en) | NOVEL OCTAHYDROPYRIDOQUINAZOLINE DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, AND USES THEREFOR, AND THE DERIVATIVE THEREOF | |
| SG11201401984VA (en) | Nicotinic receptor non-competitive modulators | |
| AU2012903295A0 (en) | a7 Nicotinic Acetylcholine Receptor Modulators and Uses Thereof-II | |
| AU2012903296A0 (en) | a7 Nicotinic Acetylcholine Receptor Modulators and Uses Thereof-I | |
| AU2013900167A0 (en) | Alpha7 Nicotinic Acetylcholine Receptor Modulators and Uses Thereof-II | |
| AU2013901443A0 (en) | a7 Nicotinic Acetylcholine Receptor Modulators and Uses Thereof - III |